CTLA4 and neoplasm: Several preclinical models suggested that a novel orally bioavailable HDAC inhibitor HBI-8000 could augment the activity of ICIs targeting either PD-1, PD-L1, or CTLA-4, and significantly reduce tumor progression [145].